孟鲁司特钠对支气管哮喘患者血清MMP-9和TIMP-1水平的影响

The effect of montelukast soudium on serum levels of MMP-9 and TIMP-1 in asthma

目的 通过采用酶联免疫吸附试验（ELISA）法测定支气管哮喘（简称哮喘）治疗前后血清中基质金属蛋白酶-9（matrix metalloproteinase-9,MMP-9）和基质金属蛋白酶组织抑制剂1（tissue inhibitor of metalloproteinases-1,TIMP-1）水平,观察白三烯受体拮抗剂孟鲁司特钠对轻度持续性哮喘患者血清中MMP-9和TIMP-1水平的影响.方法 选取轻度持续性哮喘患者61例,随机分成治疗组29例和对照组32例,治疗组使用常规治疗＋孟鲁司特钠10 mg每日一次口服,疗程为7～14 d,对照组使用常规治疗,疗程为7～14 d,采用ELISA法测定两组治疗前后血清MMP-9和TIMP-1水平,并对其变化进行分析比较.结果 ①治疗后治疗组血清MMP-9水平[（22.75±6.51） μg/L]明显低于对照组治疗后[（28.93±7.59）μg/L]（P＜0.05）;治疗组治疗前血清MMP-9水平[（29.07±7.83） μg/L]明显高于治疗组治疗后[（22.75±6.51）μg/L]（P＜0.05）.②治疗后治疗组血清TIMP-1[（10.74±4.14） μg/L]明显低于对照组治疗后[（13.75±2.59） μg/L]（P＜0.05）;治疗组治疗前血清TIMP-1水平[（13.76±3.53） μg/L]明显高于治疗组治疗后[（10.74±4.14） μg/L]（P＜0.05）.结论 孟鲁司特钠可明显降低轻度持续性哮喘患者血清中MMP-9和TIMP-1的水平.MMP-9和TIMP-1的水平可作为轻度持续性哮喘患者疗效判断的指标之一.孟鲁司特钠可能会通过下调哮喘患者血清MMP-9和TIMP-1的水平,减少气道细胞外基质沉积.

Objective Serum levels of MMP-9 and TIMP-1 in bronchial asthma （asthma） patients before and after montelukast soudium treatment were tested through ELISA to observe the effect on serum levels of MMP-9 and TIMP-1.Methods Sixty-one cases of mild persistent asthma were selected and randomly divided into 29 cases as treatment group and 32 cases as control group.The treatment group were given conventional therapy plus montelukast soudium 10 mg oral treatment once-daily for 7-14 days.While the control group were given conventional therapy for 7-14 days.Serum levels of MMP-9 and TIMP-1 before and after treatment were tested respectively using ELISA and compared with their changes.Results ①The serum level of MMP-9 [（22.75± 6.51） μg/L] in treatment group were lower than those in control groups [（28.93±7.59） μtg/L] after treatment （P 〈0.05）.However in treatment group,the before-treatment levels of MMP-9 [（29.07 ± 7.83） ng/ml] was significantly higher than those after treatment [（22.75±6.51） μg/L]（P 〈0.05）.②The levels of TIMP-1 [（10.74±4.14） μg/L] in treatment group were lower than those in control groups [（13.75±2.59） μg/L] after treatment （P 〈 0.05）.The levels of TIMP-1 [（13.76±3.53） μg/L] before treatment was significantly higher than the treatment group [（10.74±4.14） μg/L] after treatment （P 〈0.05）.Conclusions Montelukast soudium can significantly reduce the levels of serum MMP-9 and TIMP-1 with mild persistent asthma patients.The levels of MMP-9 and TIMP-1 can be used as one of efficacy judgment indicators.Montelukast soudium may reduce airway cell extracellular matrix deposition through lowered the levels of MMP-9 and TIMP-1 in asthma patient.